---
document_datetime: 2026-01-19 16:56:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/imuldosa.html
document_name: imuldosa.html
version: success
processing_time: 0.1203036
conversion_datetime: 2026-01-20 20:35:38.715277
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Search

- [Medicines](/en/medicines)
    - [Find medicine](/en/medicines)
    - [Therapeutic areas: latest updates](/en/medicines/therapeutic-areas-latest-updates)
    - [Download medicine data](/en/medicines/download-medicine-data)
    - [What we publish on medicines and when](/en/medicines/what-we-publish-medicines-when)
    - [Medicines under evaluation](/en/medicines/medicines-human-use-under-evaluation)
    - [National registers](/en/medicines/national-registers-authorised-medicines)
- [Human regulatory](/en/human-regulatory-overview)
    - [Overview](/en/human-regulatory-overview)
    - [Research and development](/en/human-regulatory-overview/research-development)
    - [Marketing authorisation](/en/human-regulatory-overview/marketing-authorisation)
    - [Post-authorisation](/en/human-regulatory-overview/post-authorisation)
    - [Medical devices](/en/human-regulatory-overview/medical-devices)
    - [Herbal products](/en/human-regulatory-overview/herbal-medicinal-products)
- [Veterinary regulatory](/en/veterinary-regulatory-overview)
    - [Overview](/en/veterinary-regulatory-overview)
    - [Research and development](/en/veterinary-regulatory-overview/research-development-veterinary-medicines)
    - [Marketing authorisation](/en/veterinary-regulatory-overview/marketing-authorisation-veterinary-medicines)
    - [Post-authorisation](/en/veterinary-regulatory-overview/post-authorisation-veterinary-medicines)
- [Committees](/en/committees)
    - [Overview](/en/committees)
    - [How the committees work](/en/committees/how-committees-work)
    - [CHMP](/en/committees/committee-medicinal-products-human-use-chmp)
    - [CVMP](/en/committees/committee-veterinary-medicinal-products-cvmp)
    - [PRAC](/en/committees/pharmacovigilance-risk-assessment-committee-prac)
    - [COMP](/en/committees/committee-orphan-medicinal-products-comp)
    - [HMPC](/en/committees/committee-herbal-medicinal-products-hmpc)
    - [CAT](/en/committees/committee-advanced-therapies-cat)
    - [PDCO](/en/committees/paediatric-committee-pdco)
    - [Working parties and other groups](/en/committees/working-parties-other-groups)
- [News &amp; events](/en/news-events)
    - [Overview](/en/news-events)
    - [News](/en/news)
    - [Events](/en/events/upcoming-events)
    - [What's new](/en/news-events/whats-new)
    - [Committee highlights](/en/news-events/committee-highlights)
    - [Publications](/en/news-and-events/publications)
    - [Press and social media](/en/news-events/press-social-media)
    - [Podcast: Inside EMA](/en/news-events/podcast-inside-ema)
    - [Open consultations](/en/news-events/open-consultations)
    - [RSS feeds](/en/news-events/rss-feeds)
- [Partners &amp; networks](/en/partners-networks)
    - [Overview](/en/partners-networks)
    - [Animal health practitioners](/en/partners-networks/animal-health-practitioners)
    - [One Health approach](/en/partners-networks/one-health-approach)
    - [Academia](/en/partners-networks/academia)
    - [EU partners](/en/partners-networks/eu-partners)
    - [International activities](/en/partners-networks/international-activities)
    - [Patients and consumers](/en/partners-networks/patients-consumers)
    - [Healthcare professionals](/en/partners-networks/healthcare-professionals)
    - [Pharmaceutical industry](/en/partners-networks/pharmaceutical-industry)
    - [Networks](/en/partners-networks/networks)
    - [Health technology assessment bodies](/en/partners-networks/health-technology-assessment-bodies)
- [About us](/en/about-us)
    - [Overview](/en/about-us)
    - [What we do](/en/about-us/what-we-do)
    - [Who we are](/en/about-us/who-we-are)
    - [How we work](/en/about-us/how-we-work)
    - [Fees](/en/about-us/fees-payable-european-medicines-agency)
    - [Support to SMEs](/en/about-us/support-smes)
    - [Annual reports and work programmes](/en/about-us/annual-reports-work-programmes)
    - [History of EMA](/en/about-us/history-ema)
    - [Careers](/en/about-us/careers)
    - [Procurement](/en/about-us/procurement-grants)
    - [Glossaries](/en/about-us/glossaries)
    - [About this website](/en/about-us/about-website)
    - [Data protection and privacy](/en/about-us/data-protection-privacy-ema)
    - [Contacts](/en/about-us/contacts-european-medicines-agency)

1. [Home](/en/homepage)
2. [Medicines](https://www.ema.europa.eu/en/medicines)
3. Imuldosa

# Imuldosa

[RSS](/en/individual-human-medicine.xml/250704)

##### Authorised

This medicine is authorised for use in the European Union

ustekinumab Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Imuldosa](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Imuldosa is a medicine used to treat:

- moderate to severe plaque psoriasis (a disease causing red, scaly patches on the skin). It is used in adults and children above the age of 6 years whose condition has not improved with, or who cannot use, other systemic (whole-body) psoriasis treatments, such as ciclosporin, methotrexate or PUVA (psoralen ultraviolet A). PUVA is a type of treatment where the patient receives a medicine called psoralen, before being exposed to ultraviolet light;
- active psoriatic arthritis (inflammation of the joints associated with psoriasis) in adults, when the condition has not improved enough with other treatments called disease-modifying anti-rheumatic drugs (DMARDs). Imuldosa may be used alone or combined with methotrexate (a DMARD);
- moderately to severely active Crohn's disease (a disease-causing inflammation of the gut) in adults whose condition has not improved enough with other treatments for Crohn's disease or who cannot receive such treatments;

Imuldosa contains the active substance ustekinumab and is a biological medicine. It is a 'biosimilar medicine'; this means that Imuldosa is highly similar to another biological medicine (the 'reference medicine') that is already authorised in the EU. The reference medicine for Imuldosa is Stelara. For more information on biosimilar medicines, see [here](https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines) .

Expand section

Collapse section

## How is Imuldosa used?

Imuldosa can only be obtained with a prescription and should be given under the supervision of a doctor who has experience in diagnosing and treating the diseases that Imuldosa is used for.

In plaque psoriasis and psoriatic arthritis, Imuldosa is injected under the skin.  The first injection is followed by a further injection 4 weeks later, and then an injection every 12 weeks.

In Crohn's disease, treatment is started with Imuldosa infusion (drip) into a vein over at least 1 hour. Eight weeks after the first infusion, Imuldosa is injected under the skin. Patients then continue with Imuldosa injected under the skin every 8 or 12 weeks depending on how well the treatment is working.

Patients or their caregivers may inject Imuldosa under the skin once they have been trained, if their doctor thinks that this is appropriate. For more information about using Imuldosa, see the package leaflet or contact your doctor or pharmacist.

## How does Imuldosa work?

The active substance in Imuldosa, ustekinumab, is a monoclonal antibody, a type of protein that has been designed to recognise and attach to a specific target in the body. Ustekinumab attaches to 2 messenger molecules in the immune system called interleukin 12 and interleukin 23. Both are involved in inflammation and other processes that are important in psoriasis, psoriatic arthritis and Crohn's disease. By blocking their activity, ustekinumab reduces the activity of the immune system and the symptoms of the disease.

## What benefits of Imuldosa have been shown in studies?

Laboratory studies comparing Imuldosa with Stelara have shown that the active substance in Imuldosa is highly similar to that in Stelara in terms of structure, purity and biological activity. Studies have also shown that giving Imuldosa produces similar levels of the active substance in the body to giving Stelara.

In addition, a study of 523 patients with moderate to severe plaque psoriasis showed that Imuldosa  was as effective as Stelara in improving symptoms. The improvement in symptoms scores after 8 weeks was similar with both medicines.

Because Imuldosa is a biosimilar medicine, the studies on effectiveness of ustekinumab carried out with Stelara do not all need to be repeated for Imuldosa.

## What are the risks associated with Imuldosa?

The safety of Imuldosa has been evaluated and, on the basis of all the studies carried out, the side effects of the medicine are considered to be comparable to those of the reference medicine Stelara.

For the complete list of side effects and restrictions of Imuldosa, see the package leaflet.

The most common side effects with ustekinumab (seen in more than 1 in 20) include headache and nasopharyngitis (inflammation of the nose and throat). The most serious side effect reported with ustekinumab include serious hypersensitivity (allergic reaction) including anaphylaxis (sudden, severe allergic reaction with breathing difficulty, swelling, lightheadedness, fast heartbeat, sweating and loss of consciousness).

Imuldosa must not be used in patients who have an active infection that the doctor considers important.

## Why is Imuldosa authorised in the EU?

The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Imuldosa has a highly similar structure, purity and biological activity to Stelara and is distributed in the body in the same way. In addition, a study in patients with plaque psoriasis has shown that Imuldosa and Stelara are equivalent in terms of safety and effectiveness in this condition.

All these data were considered sufficient to conclude that Imuldosa will have the same effects as Stelara in its authorised uses. Therefore, the Agency's view was that, as for Stelara, the benefits of Imuldosa outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Imuldosa?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Imuldosa have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Imuldosa are continuously monitored. Suspected side effects reported with Imuldosa are carefully evaluated and any necessary action taken to protect patients.

## Other information about Imuldosa

Imuldosa received a marketing authorisation valid throughout the EU on 12 December 2024.

Imuldosa : EPAR - Medicine overview

Reference Number: EMA/536424/2024

English (EN) (106.93 KB - PDF)

**First published:** 18/12/2024

**Last updated:** 06/01/2025

[View](/en/documents/overview/imuldosa-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-99)

български (BG) (127.07 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/bg/documents/overview/imuldosa-epar-medicine-overview_bg.pdf)

español (ES) (107.58 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/es/documents/overview/imuldosa-epar-medicine-overview_es.pdf)

čeština (CS) (127.22 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/cs/documents/overview/imuldosa-epar-medicine-overview_cs.pdf)

dansk (DA) (107.07 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/da/documents/overview/imuldosa-epar-medicine-overview_da.pdf)

Deutsch (DE) (107.95 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/de/documents/overview/imuldosa-epar-medicine-overview_de.pdf)

eesti keel (ET) (106.51 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/et/documents/overview/imuldosa-epar-medicine-overview_et.pdf)

ελληνικά (EL) (138.87 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/el/documents/overview/imuldosa-epar-medicine-overview_el.pdf)

français (FR) (108.26 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/fr/documents/overview/imuldosa-epar-medicine-overview_fr.pdf)

hrvatski (HR) (121.71 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/hr/documents/overview/imuldosa-epar-medicine-overview_hr.pdf)

italiano (IT) (107.3 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/it/documents/overview/imuldosa-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (127.87 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/lv/documents/overview/imuldosa-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (126.49 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/lt/documents/overview/imuldosa-epar-medicine-overview_lt.pdf)

magyar (HU) (121.53 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/hu/documents/overview/imuldosa-epar-medicine-overview_hu.pdf)

Malti (MT) (127.76 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/mt/documents/overview/imuldosa-epar-medicine-overview_mt.pdf)

Nederlands (NL) (107.9 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/nl/documents/overview/imuldosa-epar-medicine-overview_nl.pdf)

polski (PL) (127.22 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/pl/documents/overview/imuldosa-epar-medicine-overview_pl.pdf)

português (PT) (107.43 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/pt/documents/overview/imuldosa-epar-medicine-overview_pt.pdf)

română (RO) (125.27 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/ro/documents/overview/imuldosa-epar-medicine-overview_ro.pdf)

slovenčina (SK) (125.67 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/sk/documents/overview/imuldosa-epar-medicine-overview_sk.pdf)

slovenščina (SL) (121.67 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/sl/documents/overview/imuldosa-epar-medicine-overview_sl.pdf)

Suomi (FI) (106.9 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/fi/documents/overview/imuldosa-epar-medicine-overview_fi.pdf)

svenska (SV) (106.8 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/sv/documents/overview/imuldosa-epar-medicine-overview_sv.pdf)

Imuldosa : EPAR - Risk Management Plan

English (EN) (786.07 KB - PDF)

**First published:** 18/12/2024

[View](/en/documents/rmp/imuldosa-epar-risk-management-plan_en.pdf)

## Product information

Imuldosa : EPAR - Product information

English (EN) (1.98 MB - PDF)

**First published:** 18/12/2024

**Last updated:** 19/01/2026

[View](/en/documents/product-information/imuldosa-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-618)

български (BG) (1.28 MB - PDF)

**First published:**

18/12/2024

**Last updated:**

19/01/2026

[View](/bg/documents/product-information/imuldosa-epar-product-information_bg.pdf)

español (ES) (1.14 MB - PDF)

**First published:**

18/12/2024

**Last updated:**

19/01/2026

[View](/es/documents/product-information/imuldosa-epar-product-information_es.pdf)

čeština (CS) (1.22 MB - PDF)

**First published:**

18/12/2024

**Last updated:**

19/01/2026

[View](/cs/documents/product-information/imuldosa-epar-product-information_cs.pdf)

dansk (DA) (1.18 MB - PDF)

**First published:**

18/12/2024

**Last updated:**

19/01/2026

[View](/da/documents/product-information/imuldosa-epar-product-information_da.pdf)

Deutsch (DE) (1.16 MB - PDF)

**First published:**

18/12/2024

**Last updated:**

19/01/2026

[View](/de/documents/product-information/imuldosa-epar-product-information_de.pdf)

eesti keel (ET) (1.18 MB - PDF)

**First published:**

18/12/2024

**Last updated:**

19/01/2026

[View](/et/documents/product-information/imuldosa-epar-product-information_et.pdf)

ελληνικά (EL) (1.41 MB - PDF)

**First published:**

18/12/2024

**Last updated:**

19/01/2026

[View](/el/documents/product-information/imuldosa-epar-product-information_el.pdf)

français (FR) (1.4 MB - PDF)

**First published:**

18/12/2024

**Last updated:**

19/01/2026

[View](/fr/documents/product-information/imuldosa-epar-product-information_fr.pdf)

hrvatski (HR) (1.25 MB - PDF)

**First published:**

18/12/2024

**Last updated:**

19/01/2026

[View](/hr/documents/product-information/imuldosa-epar-product-information_hr.pdf)

íslenska (IS) (1.41 MB - PDF)

**First published:**

18/12/2024

**Last updated:**

19/01/2026

[View](/is/documents/product-information/imuldosa-epar-product-information_is.pdf)

italiano (IT) (931.99 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

19/01/2026

[View](/it/documents/product-information/imuldosa-epar-product-information_it.pdf)

latviešu valoda (LV) (1.2 MB - PDF)

**First published:**

18/12/2024

**Last updated:**

19/01/2026

[View](/lv/documents/product-information/imuldosa-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.31 MB - PDF)

**First published:**

18/12/2024

**Last updated:**

19/01/2026

[View](/lt/documents/product-information/imuldosa-epar-product-information_lt.pdf)

magyar (HU) (1.26 MB - PDF)

**First published:**

18/12/2024

**Last updated:**

19/01/2026

[View](/hu/documents/product-information/imuldosa-epar-product-information_hu.pdf)

Malti (MT) (1.36 MB - PDF)

**First published:**

18/12/2024

**Last updated:**

19/01/2026

[View](/mt/documents/product-information/imuldosa-epar-product-information_mt.pdf)

Nederlands (NL) (816.7 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

19/01/2026

[View](/nl/documents/product-information/imuldosa-epar-product-information_nl.pdf)

norsk (NO) (1.23 MB - PDF)

**First published:**

18/12/2024

**Last updated:**

19/01/2026

[View](/no/documents/product-information/imuldosa-epar-product-information_no.pdf)

polski (PL) (1.32 MB - PDF)

**First published:**

18/12/2024

**Last updated:**

19/01/2026

[View](/pl/documents/product-information/imuldosa-epar-product-information_pl.pdf)

português (PT) (1.18 MB - PDF)

**First published:**

18/12/2024

**Last updated:**

19/01/2026

[View](/pt/documents/product-information/imuldosa-epar-product-information_pt.pdf)

română (RO) (1.39 MB - PDF)

**First published:**

18/12/2024

**Last updated:**

19/01/2026

[View](/ro/documents/product-information/imuldosa-epar-product-information_ro.pdf)

slovenčina (SK) (1.24 MB - PDF)

**First published:**

18/12/2024

**Last updated:**

19/01/2026

[View](/sk/documents/product-information/imuldosa-epar-product-information_sk.pdf)

slovenščina (SL) (1.28 MB - PDF)

**First published:**

18/12/2024

**Last updated:**

19/01/2026

[View](/sl/documents/product-information/imuldosa-epar-product-information_sl.pdf)

Suomi (FI) (1.3 MB - PDF)

**First published:**

18/12/2024

**Last updated:**

19/01/2026

[View](/fi/documents/product-information/imuldosa-epar-product-information_fi.pdf)

svenska (SV) (1.27 MB - PDF)

**First published:**

18/12/2024

**Last updated:**

19/01/2026

[View](/sv/documents/product-information/imuldosa-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000313404 15/01/2026

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Imuldosa : EPAR - All authorised presentations

English (EN) (155.34 KB - PDF)

**First published:** 18/12/2024

[View](/en/documents/all-authorised-presentations/imuldosa-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-875)

български (BG) (161.28 KB - PDF)

**First published:**

18/12/2024

[View](/bg/documents/all-authorised-presentations/imuldosa-epar-all-authorised-presentations_bg.pdf)

español (ES) (155.63 KB - PDF)

**First published:**

18/12/2024

[View](/es/documents/all-authorised-presentations/imuldosa-epar-all-authorised-presentations_es.pdf)

čeština (CS) (158.05 KB - PDF)

**First published:**

18/12/2024

[View](/cs/documents/all-authorised-presentations/imuldosa-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (158.1 KB - PDF)

**First published:**

18/12/2024

[View](/da/documents/all-authorised-presentations/imuldosa-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (158.47 KB - PDF)

**First published:**

18/12/2024

[View](/de/documents/all-authorised-presentations/imuldosa-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (148.47 KB - PDF)

**First published:**

18/12/2024

[View](/et/documents/all-authorised-presentations/imuldosa-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (157.47 KB - PDF)

**First published:**

18/12/2024

[View](/el/documents/all-authorised-presentations/imuldosa-epar-all-authorised-presentations_el.pdf)

français (FR) (154.63 KB - PDF)

**First published:**

18/12/2024

[View](/fr/documents/all-authorised-presentations/imuldosa-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (154.97 KB - PDF)

**First published:**

18/12/2024

[View](/hr/documents/all-authorised-presentations/imuldosa-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (157.77 KB - PDF)

**First published:**

18/12/2024

[View](/is/documents/all-authorised-presentations/imuldosa-epar-all-authorised-presentations_is.pdf)

italiano (IT) (154.36 KB - PDF)

**First published:**

18/12/2024

[View](/it/documents/all-authorised-presentations/imuldosa-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (157.08 KB - PDF)

**First published:**

18/12/2024

[View](/lv/documents/all-authorised-presentations/imuldosa-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (156.41 KB - PDF)

**First published:**

18/12/2024

[View](/lt/documents/all-authorised-presentations/imuldosa-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (156.15 KB - PDF)

**First published:**

18/12/2024

[View](/hu/documents/all-authorised-presentations/imuldosa-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (157.71 KB - PDF)

**First published:**

18/12/2024

[View](/mt/documents/all-authorised-presentations/imuldosa-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (154.1 KB - PDF)

**First published:**

18/12/2024

[View](/nl/documents/all-authorised-presentations/imuldosa-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (157.03 KB - PDF)

**First published:**

18/12/2024

[View](/no/documents/all-authorised-presentations/imuldosa-epar-all-authorised-presentations_no.pdf)

polski (PL) (329.07 KB - PDF)

**First published:**

18/12/2024

[View](/pl/documents/all-authorised-presentations/imuldosa-epar-all-authorised-presentations_pl.pdf)

português (PT) (156.29 KB - PDF)

**First published:**

18/12/2024

[View](/pt/documents/all-authorised-presentations/imuldosa-epar-all-authorised-presentations_pt.pdf)

română (RO) (155.16 KB - PDF)

**First published:**

18/12/2024

[View](/ro/documents/all-authorised-presentations/imuldosa-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (157.67 KB - PDF)

**First published:**

18/12/2024

[View](/sk/documents/all-authorised-presentations/imuldosa-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (84.57 KB - PDF)

**First published:**

18/12/2024

[View](/sl/documents/all-authorised-presentations/imuldosa-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (152.88 KB - PDF)

**First published:**

18/12/2024

[View](/fi/documents/all-authorised-presentations/imuldosa-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (155.18 KB - PDF)

**First published:**

18/12/2024

[View](/sv/documents/all-authorised-presentations/imuldosa-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Imuldosa Active substance ustekinumab International non-proprietary name (INN) or common name ustekinumab Therapeutic area (MeSH)

- Crohn Disease
- Psoriasis
- Arthritis, Psoriatic

Anatomical therapeutic chemical (ATC) code L04AC05

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

Adult Crohn's Disease Imuldosa is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist or have medical contraindications to such therapies.

Paediatric Crohn's Disease Imuldosa is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients weighing at least 40 kg, who have had an inadequate response to, or were intolerant to either conventional or biologic therapy.

Plaque psoriasis Imuldosa is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate (MTX) or PUVA (psoralen and ultraviolet A).

Paediatric plaque psoriasis Imuldosa is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.

Psoriatic arthritis (PsA) Imuldosa, alone or in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease- modifying anti-rheumatic drug (DMARD) therapy has been inadequate.

## Authorisation details

EMA product number EMEA/H/C/006221

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

Accord Healthcare S.L.U.

Edificio Este Planta 6a

Opinion adopted 17/10/2024 Marketing authorisation issued 12/12/2024 Revision 4

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Imuldosa : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (159.09 KB - PDF)

**First published:** 06/06/2025

**Last updated:** 19/01/2026

[View](/en/documents/procedural-steps-after/imuldosa-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Imuldosa : EPAR - Public assessment report

Adopted

Reference Number: EMA/592044/2024

English (EN) (2.44 MB - PDF)

**First published:** 18/12/2024

[View](/en/documents/assessment-report/imuldosa-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Imuldosa

Adopted

Reference Number: EMA/CHMP/448102/2024

English (EN) (101.03 KB - PDF)

**First published:** 18/10/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-imuldosa_en.pdf)

#### News on Imuldosa

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 October 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-october-2024) 18/10/2024

**This page was last updated on** 19/01/2026

## Share this page

[Back to top](#main-content)